| You are here: Home: BCU 9|2003 - Supplement : Case 5: From the practice of Stephen A Grabelsky, MD: Select publications
Select publications
Estrogen receptor downregulator, fulvestrant
Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7(12 Suppl):4369s-4375s;discussion 4411s-4412s. Abstract
Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast cancer: Survival analysis from a Phase III trial. Proc ASCO 2003;Abstract 178.
Jones SE. A new estrogen receptor antagonist--An overview of available data. Breast Cancer Res Treat 2002;75 (Suppl 1)S19-21;discussion S33-5. Abstract
Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract
Parker LM et al. Greater duration of response in patients receiving fulvestrant ('Faslodex') compared with those receiving anastrozole ('Arimidex'). Proc ASCO 2002;Abstract 160.
Robertson JF. Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer. Clin Ther 2002;24 (Suppl A)A17-30. Abstract
Robertson JF, Harrison MP. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer. C ancer Chemother Pharmacol 2003;52(4):346-8. Abstract
|
